„Watch and wait“ bei follikulären Lymphomen – Zeit für einen Strategiewechsel?

Schlüsselwörter

follikuläre Lymphome - Watch and wait - Rituximab

Keywords

follicular lymphoma - watch and wait - rituximab

• Literatur

• 1 Ardeshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma. Lancet 2003; 362: 516-522
• 2 Ardeshna K, Qian W, Smith P et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010; 116: 6
• 3 Ardeshna K, Qian W, Stephens R et al. Preliminary results of quality of life analyses from the Intergroup phase III randomized trial of rituximab vs. a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol 2011; 22 (Suppl. 04) 109
• 4 Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-1117
• 5 Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992
• 6 Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732
• 7 Horning SJ. Follicular lymphoma: have we made any progress?. Ann Oncol 2000; 11 (Suppl. 01) 23-27
• 8 Kahl BS, Hong F, Williams ME et al. Results of the Eastern Cooperative Oncology Group protocol E 4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118: 6
• 9 Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586
• 10 Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831
• 11 Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA). Lancet 2011; 377: 42-51
• 12 Seer CSR. SEER Surveillance, Epidemiology, and End Results. In: 1975–2004. SEER Cancer Statistics 2007
• 13 Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin Hematol 1988; 25 (Suppl. 02) 11-16